计算溶液所需的质量、体积或浓度。
提供 ≥99% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
2-8°C储存,干燥。低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit ( IC 50 =200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β ( IC 50 s=540/800 nM), Lyn ( IC 50 = 510 nM for LynB), Lck , and, to a lesser extent, FGFR3 and FAK . Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity.
In Vitro
Masitinib is a competitive inhibitor against ATP at concentrations ≤500 nM. Masitinib also potently inhibits recombinant PDGFR and the intracellular kinase Lyn, and to a lesser extent, fibroblast growth factor receptor 3. Masitinib demonstrates weak inhibition of Abl and c-Fms. Masitinib more strongly inhibits degranulation, cytokine production, and bone marrow mast cell migration than imatinib. In Ba/F3 cells expressing human wild-type Kit, masitinib inhibits SCF (stem cell factor)-induced cell proliferation with an IC 50 of 150 nM, while the IC 50 for inhibition of IL-3-stimulated proliferation is at approximately >10 μM. In Ba/F3 cells expressing PDGFRα, masitinib inhibits PDGF-BB-stimulated proliferation and PDGFRα tyrosine phosphorylation with IC 50 of 300 nM. Masitinib also causes inhibition of SCF-stimulated tyrosine phosphorylation of human Kit in mastocytoma cell-lines and BMMC. Masitinib inhibits Kit gain-of-function mutants, including V559D mutant and Δ27 mouse mutant with IC 50 of 3 and 5 nM in Ba/F3 cells. Masitinib inhibits the cell proliferation of mastocytoma cell lines including HMC-1α155 and FMA3 with IC 50 of 10 and 30 nM, respectively. ?\nMasitinib inhibits cell growth and PDGFR phosphorylation in two novel ISS cell lines, which suggest that Masitinib displays activity against both primary and metastatic ISS cell line and may aid in the clinical management of ISS. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Masitinib inhibits tumour growth and increases the median survival time in Δ27-expressing Ba/F3 tumor models at 30 mg/kg, without cardiotoxicity or genotoxicity . ?\nMasitinib (12.5 mg/kg/d, p.o.) increases overall TTP (time-to-tumor progression) compared with placebo in dogs. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
IC50& Target:IC50: 200 nM (Kit), 540 nM (PDGFRα), 800 nM (PDGFRβ), 510 nM (LynB)
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 苯类化合物 |
| 类(Class) | 苯及其取代衍生物 |
| 亚类(Subclass) | 苯胺类 |
| 中间层级节点(Intermediate Tree Nodes) | 芳香族苯胺 |
| 直接上位类(Direct Parent) | 苯甲酰苯胺类 |
| 其他上位类(Alternative Parents) | 苯甲酰胺类 二氨基甲苯 苯胺和取代苯胺 苯甲胺 苯甲酰衍生物 苄胺 2,4-二取代噻唑 芳烷基胺 N-甲基哌嗪 2-氨基-1,3-噻唑 吡啶及其衍生物 磺酰基 烷磺酸 有机磺酸 甲磺酸盐 杂芳族化合物 三烷基胺 氨基酸及其衍生物 仲羧酸酰胺 氮杂环化合物 有机氧化合物 有机氧化物 碳氢化合物衍生物 |
| 分子骨架(Molecular Framework) | 暂无 |
| 取代基(Substituents) | 1,3-噻唑-2-胺 - 1,4-二氮杂环丁烷 - 2,4-二取代-1,3-噻唑 - 烷烷磺酸 - 氨基酸 - 氨基酸或其衍生物 - 苯胺或取代苯胺 - 芳烷基胺 - 芳香族杂单环化合物 - 氮杂环 - 吡唑 - 苯甲酰胺 - 苯甲酰胺 - 苯甲酸或衍生物 - 苯甲酰 - 苄胺 - 羧酰胺基 - 羧酸衍生物 - 二氨基甲苯 - 杂芳香族化合物 - 烃衍生物 - 甲磺酸盐 - N-烷基哌嗪 - N-甲基哌嗪 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机磺酸或其衍生物 - 有机杂环化合物 - 有机氮化合物 - 有机氧化合物 - 有机硒化合物 - 有机磺酸或其衍生物 - 有机硫化合物 - 苯甲胺 - 哌嗪 - 吡啶 - 醛基 - 磺酰基 - 三元脂肪胺 - 三芳基胺 - 噻唑 - 甲苯 |
| 描述(Description) | 该化合物属于苯甲酰胺类有机化合物。这类芳香化合物含有酰胺基团,其中羧酰胺基被苯环取代。其通式为RNC(=O)R',其中R、R'=苯环。 |
| 外部描述符(External Descriptors) | 暂无 |